Germany Pneumococcal Vaccines Market Size, Share & Industry Analysis, By Product Type (PCV10, PCV13, and PPSV23), By End User (Hospitals, Clinics, and Others) and Region Forecast, 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Germany Pneumococcal Vaccines Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Germany Pneumococcal Vaccines market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Germany Pneumococcal Vaccines market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Germany Pneumococcal Vaccines Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Germany Pneumococcal Vaccines Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Germany Pneumococcal Vaccines Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Pfizer, and Merck & Co. Inc. Dominate the German Pneumococcal Vaccines Market
The Germany pneumococcal vaccines market is characteristically a consolidated market, with very few players operating in the global space. The market consists of a monopoly comprising of Pfizer, especially in the pneumococcal conjugate vaccines space (PCV), while a small share of the PCV segment is captured by GlaxoSmithKline plc. In the pneumococcal polysaccharide market space (PPSV23), a major chunk of market share is captured by Merck & Co., Inc., along with Sanofi and Pfizer. A strong distribution network and higher preference of healthcare providers for PCV13 (Prevenar 13) from Pfizer, along with comparatively high price of the vaccine, are some of the major factors responsible for the dominant share of the company in the global market in 2018. The approval of its 20vPnc (a 20-valent PCV vaccine) which is currently entering phase-3 clinical trials, is expected to be further augment the share of the company. Merck & Co., Inc., is projected to increase its market share amongst the key market players during the forecast period, based on projections which include successful launch of its 15-valent PCV vaccine (V-114) during the forecast period. The 15-valent PCV vaccine (V-114) recently exhibited positive results in its clinical trials. These vaccine candidates are anticipated to be launched in Europe and this also is anticipated to further strengthen the market in Germany.

LIST OF KEY COMPANIES PROFILED:

  
Pfizer
  
Merck & Co. Inc.
  
GlaxoSmithKline plc
  
Sanofi

REPORT COVERAGE

The increased demand for effective vaccinations, a stringent government vaccination policy and the adoption of advanced and technologically superior pneumococcal vaccines are expected to contribute to the Germany pneumococcal vaccines market growth.

Along with this, the report provides an elaborative analysis of the Germany market dynamics and competitive landscape. Various key insights presented in the report are pipeline analysis of key global players, pricing analysis of key products (2018), key mergers and acquisitions, prevalence of pneumonia in various regions of Germany, and immunization coverage of pediatric patients in Germany, among others.

Report Scope & Segmentation

Segmentation

By Product Type

  
PCV10
  
PCV13
  
PPSV23

By End User

  
Hospitals
  
Clinics
  
Others

By Country

  
Baden-Wurttemberg
  
Bayern
  
Nordrhein-Westfalen
  
Hessen
  
Niedersachsen
  
Sachsen
  
Berlin
  
Others

INDUSTRY DEVELOPMENT:

August 2016: The German Committee on Vaccination (StAndige Impfkommission or STIKO) announced an updating of the German pneumococcal vaccination policy recommending pneumococcal vaccination through a sequential vaccination scheme, i.e. pneumococcal conjugate vaccine (PCV13) followed by pneumococcal polysaccharide vaccine (PPSV23) post six months and a booster with PPSV23 every six years in immune-incompetent or high risk patients aged two years and older as well as in children and adolescents aged 2-15 years with selected underlying chronic diseases also classified as high risk patients.